Xpert human papillomavirus test is a promising cervical cancer screening test for HIV-seropositive women.

ABSTRACT: This study investigated the performance of Cepheid Xpert human papillomavirus (HPV) assay in South African human immunodeficiency virus (HIV)-infected women and compared its performance with that of hybrid capture-2 (hc2).

Methods

Stored cervical specimens from HIV-infected women that had previously been tested using hc2 were tested using Xpert.

Results

The overall HR-HPV prevalence was found to be 62.0% (720/1161) by Xpert and 61.2% (711/1161) by hc2. 13.6% (158/1161) were HPV16 positive, 18.8% (218/1161) were HPV18/45, 37.3% (434/1161) were HPV31/33/35/52/58, 12.7% (147/1161) were HPV51/59 and 23.3% (270/1161) were HPV39/68/56/66. Overall agreement with hc2 was 90%; Cohen's kappa was 0.78 (95% CI 0.74-0.82) indicating substantial agreement. Detection of HPV16, HPV18/45, and

SUBMITTER: Mbulawa ZZA 

PROVIDER: S-EPMC5886871 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature